F
Fluxome
Discovering, producing, and supplying innovative, sustainable ingredients — in particular for health, wellness and nutrition
About Fluxome
Fluxome operates in the biotechnology sector, specializing in the development and supply of nature-based flavors, fragrances, and health ingredients. The company serves a wide range of clients across various industries, including food and beverage, health and wellness, and personal care. Fluxome's business model revolves around the production and sale of high-quality, sustainable ingredients such as nootkatone, valencene, vanillin, and resveratrol. These ingredients are used in products that cater to the growing consumer demand for natural and health-conscious options. The company generates revenue through direct sales to manufacturers and businesses that incorporate these ingredients into their products. Fluxome's market is global, with a focus on regions with high growth potential. The company also offers tailored technology services to meet specific client needs, further diversifying its revenue streams.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- Stenløse, Denmark
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 55.8/100
- Industry
- Health, Fintech
- Sub-industry
- BioTechnology, Wealth Management
- Sector
- Biotech & Life Sciences, Supply Chain Management, Natural Resources, Dietary Supplements, Biotechnology, DNA, Genetics and genomics, Nutrition, Spinout, Genome Engineering
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Fluxome.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2012 | $0 | — | Evolva | — |
| LATE VC✓Equity / VC | Dec 2011 | — | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Fluxome is 0 monthly website visits. Fluxome's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Vecata
Seventure Partners
Incuba Venture
Danish Venture Capital and Private Equity Association
Capricorn Partners
Other known investors4 additional known investors
Evolva
Technical University of Denmark
Export and Investment Fund of Denmark
INCUBA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fluxome on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fluxome’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.